MSH’s Dr. Rabia Sucu Named President of Health Technology Assessment International, Board of Directors

Arlington, VA—June 28, 2023—MSH congratulates Dr. Rabia Sucu for her appointment as president of both Health Technology Assessment international (HTAi), a nonprofit organization dedicated to fostering health technology assessments worldwide, and the organization’s board of directors. The appointment follows Dr. Sucu’s previous term as vice president, which began in 2021. Dr. Sucu is MSH’s principal technical advisor for pharmaceutical policy and governance for the USAID SAFEMed Activity in Ukraine, where she has led SAFEMed’s work to institutionalize Health Technology Assessment in Ukraine, in addition to improving policies around pharmaceutical pricing and reimbursement strategies. She has served as a board director with HTAi since 2014, chaired the HTAi Developing Countries Interest Group, and co-chaired the Medical Devices Interest Group. In addition, she served as the Chair of the Eurasian Health Technology Assessment (HTA) Initiative.

A medical doctor with a degree in HTA, Dr. Sucu has authored more than 150 peer-reviewed journal articles and eight books and has delivered more than 300 scientific presentations at international meetings on HTA. Prior to joining MSH, Dr. Sucu was the director of the Health Technology Assessment Unit at Ankara Numune Training and Research Hospital in Ankara, Turkey, and a professor of family medicine at the same hospital. She has contributed to numerous national and international projects around HTA, including the European Network for Health Technology Assessment (EUnetHTA) and Adopting Hospital-Based Health Technology Assessment (AdHopHTA). In 2017, Dr. Sucu served as the national clinical quality coordinator of the Turkish Ministry of Health, where she coordinated all activities involving HTA, clinical guidelines, and quality.

Dr. Sucu’s previous roles include serving on the Pharmaceuticals Reimbursement Committee of the Turkish Social Security Institution during the transition to universal health coverage, and she co-authored the reimbursement guidelines. She worked at the Turkish Medicines Agency on pricing and reimbursement of pharmaceuticals and led the agency’s HTA work.

More information about MSH’s approach to HTA is available here. Click here to learn more about HTAi.